Invention Grant
- Patent Title: Pharmaceutical salts of an orexin receptor antagonist
-
Application No.: US15305246Application Date: 2015-04-16
-
Publication No.: US09969725B2Publication Date: 2018-05-15
- Inventor: Michael McNevin , Sachin Lohani
- Applicant: MERCK SHARP & DOHME CORP.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent J. Eric Thies; John C. Todaro
- International Application: PCT/US2015/026060 WO 20150416
- International Announcement: WO2015/164160 WO 20151029
- Main IPC: C07D249/06
- IPC: C07D249/06 ; C07D413/14 ; A61K31/551 ; C07C305/04 ; C07C309/04 ; C07C309/30 ; C07C305/06 ; C07C309/66
Abstract:
The invention is directed to pharmaceutically acceptable salts of suvorexant, which is an antagonist of orexin receptors. The pharmaceutically acceptable salts of suvorexant are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is further directed to pharmaceutical compositions comprising pharmaceutically acceptable salts of suvorexant.
Public/Granted literature
- US20170044149A1 PHARMACEUTICAL SALTS OF AN OREXIN RECEPTOR ANTAGONIST Public/Granted day:2017-02-16
Information query
